Online inquiry

IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14074MR)

This product GTTS-WQ14074MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14074MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6621MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2319MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ2631MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ8174MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ6569MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ9196MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ15305MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ12143MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW